Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + fluorouracil + methotrexate
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen that includes four anticancer drugs: cyclophosphamide, doxorubicin (also known as Adriamycin or hydroxydaunorubicin), fluorouracil (5-FU), and methotrexate. Each drug works through different mechanisms to attack cancer cells. Cyclophosphamide is an alkylating agent that damages DNA by binding to it and causing cross-links. Doxorubicin is an anthracycline that damages DNA by inserting itself between DNA bases. Fluorouracil and methotrexate are antimetabolites that stop cells from making and repairing DNA, causing cell death when they try to divide.
- Other names
- FAC + MTXFACM
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + fluorouracil + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + methotrexate.